<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01928082</url>
  </required_header>
  <id_info>
    <org_study_id>12-0062</org_study_id>
    <nct_id>NCT01928082</nct_id>
  </id_info>
  <brief_title>The Effects of Estrogen Replacement Therapy in Postmenopausal Women With Hypercalciuria and Low Bone Mass</brief_title>
  <official_title>The Effects of Estrogen Replacement Therapy in Postmenopausal Women With Hypercalciuria and Low Bone Mass</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess if estrogen replacement normalizes urinary calcium
      excretion in postmenopausal women with hypercalciuria and low bone mass and to assess for
      differences in response to estrogen replacement in women with familial hypercalciuria
      compared to nonfamilial hypercalciuria.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will primarily be recruited from the subjects of protocol 12-1421. Subjects may also
      be identified through chart review of patients seen by Dr. Favus in the Bone Clinic at the
      University of Chicago. These subjects will be mailed a letter describing the study and a
      request to contact us if they are willing to participate in the study.

      We plan to enroll 20 subjects to obtain complete data on 16 subjects. We aim to have 10
      subjects who will have confirmed familial idiopathic hypercalciuria (IH) and 10 subjects who
      will have no family history of hypercalciuria.

      Subjects will be brought into the Clinical Research Center at the University of Chicago where
      blood samples will be collected by phlebotomy to obtain the following screening tests:
      complete metabolic panel; including calcium, phosphate, magnesium, creatinine, aspartate
      aminotransferase (AST), alanine aminotransferase (ALT), and albumin; parathyroid hormone,
      25-hydroxyvitamin D, follicle stimulating hormone (FSH), and estradiol. A twenty-four hour
      urine collection starting with second void of the day will be collected for calcium,
      phosphate, magnesium, citrate, oxalate, sodium, ammonia, sulfate, and creatinine. Subjects on
      diuretics will be screened after a 2 week washout period, provided this can be discontinued
      safely. If subjects have participated in study protocol number 12-1421, these screening tests
      do not have to be repeated and the results from protocol number 12-1421 will be used to
      determine eligibility.

      Screening subjects who meet inclusion criteria can proceed to the observational study.
      Screening subjects who are vitamin D depleted (serum 25-hydroxyvitamin D less than 35 ng/mL)
      may be rescreened after repletion of vitamin D.

      A letter describing the study aims, protocols, and risks and benefits will be sent to their
      primary care physicians and gynecologists. Upon completion of the study, a summary letter
      will be sent as well.

      Prior to the baseline visit a twenty-four hour urine collection starting with the second void
      of the day will be collected for calcium, phosphate, magnesium, citrate, oxalate, sodium,
      ammonia, sulfate, and creatinine. Subjects on diuretics will require a 2 week washout period,
      provided this can be discontinued safely. During the baseline visit a medical history will be
      taken and a physical exam will be performed. Venous blood will be collected for
      1,25-dihydroxyvitamin D3, osteocalcin, bone-specific alkaline phosphatase, C-telopeptides of
      type 1 collagen (CTX), procollagen type 1 N-terminal propeptide (P1NP), bone morphogenetic
      protein 2 (BMP-2), and sclerostin. If the subject has had these blood tests performed in the
      preceding four months for protocol 12-1421, the blood tests will not be repeated. 18F sodium
      fluoride PET/CT bone scan will be performed. The protocol for the radionuclide imaging is
      attached.

      All subjects will be started on transdermal 17-beta-estradiol 0.05 mg/d, which is equivalent
      to the standard dose of conjugated estrogen dose of 0.625 mg, for 4 weeks and increased to
      0.1 mg for subsequent 4 weeks. Given the short duration of this study, progesterone will not
      be provided, as 8 weeks is not of sufficient duration to significantly increase the risk of
      endometrial cancer (Strom, Schinnar et al. 2006).

      For the entire study, diuretics will be discontinued if it has been deemed safe to do so by
      the principle investigator or prescribing physician. Throughout the study, subject will
      maintain 900-1200 mg of dietary calcium daily. To monitor dietary calcium intake, a 5 day
      diet diary will be kept from Sunday to Thursday of the fourth week of each medication dose.
      Compliance of the study medication will be assessed by estrogen patch counts.

      The following blood tests will be repeated 4 and 8 weeks after starting estradiol patch:
      complete metabolic panel (including calcium, phosphate, potassium, bicarbonate, chloride,
      magnesium, creatinine, and albumin), 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D3,
      parathyroid hormone, estradiol, osteocalcin, bone-specific alkaline phosphatase,
      C-telopeptides of type 1 collagen (CTX), procollagen type 1 N-terminal propeptide (P1NP),
      bone morphogenetic protein 2 (BMP-2), and sclerostin. In addition, 4 and 8 weeks after
      starting estradiol patch, 24 hour urine collection will be performed for calcium, phosphate,
      magnesium, citrate, oxalate, sodium, ammonia, sulfate, and creatinine.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The fellow conducting the recruitment and screening left the institution
  </why_stopped>
  <start_date type="Actual">August 1, 2013</start_date>
  <completion_date type="Actual">August 1, 2014</completion_date>
  <primary_completion_date type="Actual">August 1, 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute Change in 24 Hour Urinary Calcium Excretion</measure>
    <time_frame>4 weeks, 8 weeks</time_frame>
    <description>0 participants were measured because the study was terminated</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum 1,25-dihydroxyvitamin D3</measure>
    <time_frame>4 weeks, 8 weeks</time_frame>
    <description>0 participants were analyzed because the study was terminated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Bone Morphogenetic Protein 2</measure>
    <time_frame>4 weeks, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Sclerostin</measure>
    <time_frame>4 weeks, 8 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Serum Estradiol</measure>
    <time_frame>4 weeks, 8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Serum Total Calcium</measure>
    <time_frame>4 weeks, 8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Calculated Serum Ionized Calcium</measure>
    <time_frame>4 weeks, 8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Calculated Tubular Resorption of Calcium</measure>
    <time_frame>4 weeks, 8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Serum 25 Hydroxyvitamin D</measure>
    <time_frame>4 weeks, 8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Serum Parathyroid Hormone</measure>
    <time_frame>4 weeks, 8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Serum Phosphorus</measure>
    <time_frame>4 weeks, 8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Serum Osteocalcin</measure>
    <time_frame>4 weeks, 8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Serum Bone-specific Alkaline Phosphatase</measure>
    <time_frame>4 weeks, 8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Serum C-telopeptides of Type 1 Collagen</measure>
    <time_frame>4 weeks, 8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Serum Procollagen Type 1 N-terminal Propeptide</measure>
    <time_frame>4 weeks, 8 weeks</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Hypercalciuria</condition>
  <condition>Hypercalciuria, Familial Idiopathic</condition>
  <condition>Osteopenia</condition>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Transdermal estradiol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transdermal estradiol 0.05 mg/day for 4 weeks, followed by 0.10 mg/day for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transdermal estradiol</intervention_name>
    <description>4 weeks of Vivelle-Dot 0.05 mg/day followed by 4 weeks of Vivelle-Dot 0.10 mg/day</description>
    <arm_group_label>Transdermal estradiol</arm_group_label>
    <other_name>Vivelle-Dot 0.05 mg/day</other_name>
    <other_name>Vivelle-Dot 0.10 mg/day</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal women

          -  Diagnosis of hypercalciuria

          -  Diagnosis of low bone mass

          -  Vitamin D replete (serum 25-hydroxyvitamin D level &gt;35 ng/mL)

        Exclusion Criteria:

          -  Secondary causes of hypercalciuria (primary hyperparathyroidism, sarcoidosis, vitamin
             D excess, malignant neoplasm, and renal tubular acidosis)

          -  Other metabolic bone disease (primary hyperparathyroidism, hyperthyroidism,
             hypercortisolemia, severe gastrointestinal disorders, liver cirrhosis, renal failure
             (Cr &gt;1.5), active malignancy including multiple myeloma, rheumatological diseases, and
             Paget's disease of bone)

          -  Use of medications affecting bone and calcium metabolism (corticosteroids in the
             previous 3 months, suppressive dose of thyroid hormone, calcium channel blockers,
             anti-convulsants, aromatase inhibitors, thiazolidinediones, and cyclosporine A)

          -  History of coronary artery disease

          -  Breast cancer or suspected estrogen-dependent neoplasia

          -  Previous venous thromboembolic event

          -  Stroke

          -  Active liver disease

          -  Tobacco use within the past 6 months

          -  Negative colonoscopy within the previous 10 years or sigmoidoscopy within the previous
             5 years

          -  Negative mammogram within the previous 2 years

          -  Negative Pap smear within the previous 3 years in women &lt; or = 65 years old with an
             intact cervix

          -  No vaginal bleeding within the prior 5 months.

          -  Age &gt; or = 70

          -  &gt; or = 20 years since last menstrual period or use of hormone replacement therapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Murray J Favus, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cerdá Gabaroi D, Peris P, Monegal A, Albaladejo C, Martínez MA, Muxí A, Martínez de Osaba MJ, Surís X, Guañabens N. Search for hidden secondary causes in postmenopausal women with osteoporosis. Menopause. 2010 Jan-Feb;17(1):135-9. doi: 10.1097/gme.0b013e3181ade8e5.</citation>
    <PMID>19593233</PMID>
  </reference>
  <reference>
    <citation>Christiansen C, Riis BJ, Rødbro P. Prediction of rapid bone loss in postmenopausal women. Lancet. 1987 May 16;1(8542):1105-8.</citation>
    <PMID>2883442</PMID>
  </reference>
  <reference>
    <citation>Deutschmann HA, Weger M, Weger W, Kotanko P, Deutschmann MJ, Skrabal F. Search for occult secondary osteoporosis: impact of identified possible risk factors on bone mineral density. J Intern Med. 2002 Nov;252(5):389-97.</citation>
    <PMID>12528756</PMID>
  </reference>
  <reference>
    <citation>Favus MJ, Karnauskas AJ, Parks JH, Coe FL. Peripheral blood monocyte vitamin D receptor levels are elevated in patients with idiopathic hypercalciuria. J Clin Endocrinol Metab. 2004 Oct;89(10):4937-43.</citation>
    <PMID>15472188</PMID>
  </reference>
  <reference>
    <citation>Frumar AM, Meldrum DR, Geola F, Shamonki IM, Tataryn IV, Deftos LJ, Judd HL. Relationship of fasting urinary calcium to circulating estrogen and body weight in postmenopausal women. J Clin Endocrinol Metab. 1980 Jan;50(1):70-5.</citation>
    <PMID>7350188</PMID>
  </reference>
  <reference>
    <citation>Giannini S, Nobile M, Dalle Carbonare L, Lodetti MG, Sella S, Vittadello G, Minicuci N, Crepaldi G. Hypercalciuria is a common and important finding in postmenopausal women with osteoporosis. Eur J Endocrinol. 2003 Sep;149(3):209-13.</citation>
    <PMID>12943523</PMID>
  </reference>
  <reference>
    <citation>Lobo RA, Roy S, Shoupe D, Endres DB, Adams JS, Rude RK, Singer FR. Estrogen and progestin effects on urinary calcium and calciotropic hormones in surgically-induced postmenopausal women. Horm Metab Res. 1985 Jul;17(7):370-3.</citation>
    <PMID>3161813</PMID>
  </reference>
  <reference>
    <citation>McKane WR, Khosla S, Burritt MF, Kao PC, Wilson DM, Ory SJ, Riggs BL. Mechanism of renal calcium conservation with estrogen replacement therapy in women in early postmenopause--a clinical research center study. J Clin Endocrinol Metab. 1995 Dec;80(12):3458-64.</citation>
    <PMID>8530583</PMID>
  </reference>
  <reference>
    <citation>Nordin BE, Horowitz M, Need A, Morris HA. Renal leak of calcium in post-menopausal osteoporosis. Clin Endocrinol (Oxf). 1994 Jul;41(1):41-5.</citation>
    <PMID>8050130</PMID>
  </reference>
  <reference>
    <citation>Nordin BE, WIshart JM, Clifton PM, McArthur R, Scopacasa F, Need AG, Morris HA, O'Loughlin PD, Horowitz M. A longitudinal study of bone-related biochemical changes at the menopause. Clin Endocrinol (Oxf). 2004 Jul;61(1):123-30.</citation>
    <PMID>15212654</PMID>
  </reference>
  <reference>
    <citation>Nordin BE, Need AG, Morris HA, Horowitz M. Biochemical variables in pre- and postmenopausal women: reconciling the calcium and estrogen hypotheses. Osteoporos Int. 1999;9(4):351-7.</citation>
    <PMID>10550453</PMID>
  </reference>
  <reference>
    <citation>Nordin BE, Need AG, Morris HA, Horowitz M, Robertson WG. Evidence for a renal calcium leak in postmenopausal women. J Clin Endocrinol Metab. 1991 Feb;72(2):401-7.</citation>
    <PMID>1991810</PMID>
  </reference>
  <reference>
    <citation>Puche RC, Roveri E, Perez Jimeno N, Roberti A, Poudes G, Bocanera R, Tozzini R. Hypercalciuria and urinary saturation measurements in climacteric women. Maturitas. 1993 Jan;16(1):39-47.</citation>
    <PMID>8429802</PMID>
  </reference>
  <reference>
    <citation>Stock JL, Coderre JA, Mallette LE. Effects of a short course of estrogen on mineral metabolism in postmenopausal women. J Clin Endocrinol Metab. 1985 Oct;61(4):595-600.</citation>
    <PMID>2993339</PMID>
  </reference>
  <reference>
    <citation>Voetberg GA, Netelenbos JC, Kenemans P, Peters-Muller ER, van de Weijer PH. Estrogen replacement therapy continuously combined with four different dosages of dydrogesterone: effect on calcium and lipid metabolism. J Clin Endocrinol Metab. 1994 Nov;79(5):1465-9.</citation>
    <PMID>7962344</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 20, 2013</study_first_submitted>
  <study_first_submitted_qc>August 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2013</study_first_posted>
  <results_first_submitted>October 12, 2017</results_first_submitted>
  <results_first_submitted_qc>February 5, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 7, 2018</results_first_posted>
  <last_update_submitted>February 5, 2018</last_update_submitted>
  <last_update_submitted_qc>February 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypercalciuria, Familial Idiopathic</keyword>
  <keyword>Hypercalciuria</keyword>
  <keyword>Osteopenia</keyword>
  <keyword>Osteoporosis</keyword>
  <keyword>Postmenopausal women</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
    <mesh_term>Hypercalciuria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Transdermal Estradiol</title>
          <description>Transdermal estradiol 0.05 mg/day for 4 weeks, followed by 0.10 mg/day for 4 weeks
Transdermal estradiol: 4 weeks of Vivelle-Dot 0.05 mg/day followed by 4 weeks of Vivelle-Dot 0.10 mg/day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study terminated.</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>data were not collected</population>
      <group_list>
        <group group_id="B1">
          <title>Transdermal Estradiol</title>
          <description>Transdermal estradiol 0.05 mg/day for 4 weeks, followed by 0.10 mg/day for 4 weeks
Transdermal estradiol: 4 weeks of Vivelle-Dot 0.05 mg/day followed by 4 weeks of Vivelle-Dot 0.10 mg/day</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Study terminated</population>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Study terminated.</population>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Absolute Change in 24 Hour Urinary Calcium Excretion</title>
        <description>0 participants were measured because the study was terminated</description>
        <time_frame>4 weeks, 8 weeks</time_frame>
        <population>0 participants were analyzed because the study was terminated</population>
        <group_list>
          <group group_id="O1">
            <title>Transdermal Estradiol</title>
            <description>Transdermal estradiol 0.05 mg/day for 4 weeks, followed by 0.10 mg/day for 4 weeks
Transdermal estradiol: 4 weeks of Vivelle-Dot 0.05 mg/day followed by 4 weeks of Vivelle-Dot 0.10 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in 24 Hour Urinary Calcium Excretion</title>
          <description>0 participants were measured because the study was terminated</description>
          <population>0 participants were analyzed because the study was terminated</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum 1,25-dihydroxyvitamin D3</title>
        <description>0 participants were analyzed because the study was terminated</description>
        <time_frame>4 weeks, 8 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Bone Morphogenetic Protein 2</title>
        <time_frame>4 weeks, 8 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Sclerostin</title>
        <time_frame>4 weeks, 8 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Serum Estradiol</title>
        <time_frame>4 weeks, 8 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Serum Total Calcium</title>
        <time_frame>4 weeks, 8 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Calculated Serum Ionized Calcium</title>
        <time_frame>4 weeks, 8 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Calculated Tubular Resorption of Calcium</title>
        <time_frame>4 weeks, 8 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Serum 25 Hydroxyvitamin D</title>
        <time_frame>4 weeks, 8 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Serum Parathyroid Hormone</title>
        <time_frame>4 weeks, 8 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Serum Phosphorus</title>
        <time_frame>4 weeks, 8 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Serum Osteocalcin</title>
        <time_frame>4 weeks, 8 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Serum Bone-specific Alkaline Phosphatase</title>
        <time_frame>4 weeks, 8 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Serum C-telopeptides of Type 1 Collagen</title>
        <time_frame>4 weeks, 8 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Serum Procollagen Type 1 N-terminal Propeptide</title>
        <time_frame>4 weeks, 8 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>adverse event data were not collected because the study was terminated</desc>
      <group_list>
        <group group_id="E1">
          <title>Transdermal Estradiol</title>
          <description>Transdermal estradiol 0.05 mg/day for 4 weeks, followed by 0.10 mg/day for 4 weeks
Transdermal estradiol: 4 weeks of Vivelle-Dot 0.05 mg/day followed by 4 weeks of Vivelle-Dot 0.10 mg/day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination leading to 0 subjects analyzed</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Murray J. Favus</name_or_title>
      <organization>The University of Chicago</organization>
      <phone>(773) 702-6138</phone>
      <email>mfavus@medicine.bsd.uchicago.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

